Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol

References

• Luczak ED, Leinwand LA. Sex-based cardiac physiology. Annu Rev Physiol 2009;71:1–18
   PubMed Web of Science ®Google Scholar
• Vitale C, Miceli M, Rosano GM. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric 2007; 10(Suppl 2):16–20
   PubMed Web of Science ®Google Scholar
• Peters HW, Westendorp IC, Hak AE, . Menopausal status and risk factors for cardiovascular disease. J Intern Med 1999;246:521–8
   PubMed Web of Science ®Google Scholar
• Verhoeven MO, van der Mooren MJ, Teerlink T, Verheijen RH, Scheffer PG, Kenemans P. The influence of physiological and surgical menopause on coronary heart disease risk markers. Menopause 2009;16:37–49
   PubMed Web of Science ®Google Scholar
• Saltiki K, Cimponeriu A, Lili K, Peppa M, Anastasiou E, Alevizaki M. Severity of coronary artery disease in postmenopausal diabetic women. Hormones (Athens) 2008;7:148–55
   PubMedGoogle Scholar
• Peverill RE, Teede HJ, Malan E, Kotsopoulos D, Smolich JJ, McGrath BP. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women. Clin Sci (Lond) 2007;113:383–91
   PubMed Web of Science ®Google Scholar
• Van Pelt RE, Schwartz RS, Kohrt WM. Insulin secretion and clearance after subacute estradiol administration in postmenopausal women. J Clin Endocrinol Metab 2008;93:484–90
   PubMed Web of Science ®Google Scholar
• Ling S, Komesaroff P, Sudhir K. Cellular mechanisms underlying the cardiovascular actions of estrogens. Clin Sci (Lond) 2006; 111:107–18
   PubMed Web of Science ®Google Scholar
• Dourakis SP, Tolis G. Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care 1998;3:7–16
   PubMedGoogle Scholar
• Kwok S, Selby PL, McElduff P, . Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving estrogen replacement therapy. Clin Endocrinol (Oxf) 2004;61:760–7
   PubMed Web of Science ®Google Scholar
• Foster RH, Balfour JA. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging 1997;11:309–32
   PubMed Web of Science ®Google Scholar
• Anderson GL, Kooperberg C, Geller N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting of the Women’s Health Initiative randomized hormone therapy trials. Clin Trials 2007; 4:207–17
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, .; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49–57
   PubMed Web of Science ®Google Scholar
• Reissigová J, Tomecková M. State of the art coronary heart disease risk estimations based on the Framingham Heart Study. Cent Eur J Public Health 2005;13:180–6
   PubMedGoogle Scholar
• Bonduki CE, Lourenço DM, Motta EL, Soares Jr JM, Haidar MA, Baracat EC. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. Clinics (Sao Paulo) 2007;62: 553–60
   PubMed Web of Science ®Google Scholar
• Kaya C, Cengiz SD, Cengiz B, Akgun G. Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthy postmenopausal women: a 1-year, randomized, prospective study. Gynecol Endocrinol 2007;23(Suppl 1):62–7
   PubMed Web of Science ®Google Scholar
• Nieto JJ, Cogswell D, Jesinger D, Hardiman P. Lipid effects of hormone replacement therapy with sequential transdermal 17- beta-estradiol and oral dydrogesterone. Obstet Gynecol 2000; 95:111–14
   PubMed Web of Science ®Google Scholar
• Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study. Eur J Obstet Gynecol Reprod Biol 1992;47:153–60
   PubMed Web of Science ®Google Scholar
• Lee CC, Kasa-Vubu JZ, Supiano MA. Androgenicity and obesity are independently associated with insulin sensitivity in postmenopausal women. Metabolism 2004;53:507–12
   PubMed Web of Science ®Google Scholar
• Yüksel H, Odabasi AR, Demircan S, Köseoğlu K, Kizilkaya K, Onur E. Effects of postmenopausal hormone replacement therapy on body fat composition. Gynecol Endocrinol 2007;23:99–104
   PubMed Web of Science ®Google Scholar
• Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001;103: 2903–8
   PubMed Web of Science ®Google Scholar
• Mikkola T, Viinikka L, Ylikorkala O. Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. Eur J Obstet Gynecol Reprod Biol 1998;79:75–82
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens 200;19:744–9
   Google Scholar
• Stevenson JC. Mechanisms whereby estrogens influence arterial health. Eur J Obstet Gynecol Reprod Biol 1996;65: 39–42
   PubMed Web of Science ®Google Scholar
• Graff-Iversen S, Thelle DS, Hammar N. Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil 2008;15:83–8
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, .; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/ progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1–9
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139: 802–9
   PubMed Web of Science ®Google Scholar
• Berg GA, Siseles N, González AI, Ortiz OC, Tempone A, Wikinski RW. Higher values of hepatic lipase activity in postmenopause: relationship with atherogenic intermediate density and low density lipoproteins. Menopause 2001;8:51–7
   PubMed Web of Science ®Google Scholar
• Haines CJ, Chung TK, Masarei JR, Tomlinson B, Lau JT. The effect of percutaneous estrogen replacement therapy on Lp(a) and other lipoproteins. Maturitas 1995;22:219–25
   PubMed Web of Science ®Google Scholar